Key facts
- Notable investors include Modoo Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Quorum Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Quorum Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Quorum Bio
Developer of biological therapeutics intended for addressing bacterial infections, metabolic disorders, and cancer. The company's platform applies quorum sensing inhibition to block biofilm formation and virulence without killing bacteria, while also advancing compounds such as oral GLP-1 galactose and non-toxic anticancer agents, enabling healthcare researchers, clinicians, and veterinary practitioners to access safer, resistance-avoiding, and long-term treatment options with reduced toxicity and broader therapeutic potential.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2013
- Website
- quorumbio.com/
- Ownership
- Privately Held (backing)
Quorum Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Quorum Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Quorum Bio in its N-PORT filings yet. We sweep new filings monthly.